You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Becton Dickinson and Company (BDX $145.31)
- $145.31 P/E (TTM): 24.55X Cap: $42.57B
- View BDX Profile
- View Questions on BDX
Stryker Corporation (SYK $315.13)
- $315.13 P/E (TTM): 39.07X Cap: $123.10B
- View SYK Profile
- View Questions on SYK
Waters Corporation (WAT $292.13)
- $292.13 P/E (TTM): 27.86X Cap: $29.52B
- View WAT Profile
- View Questions on WAT
Zoetis Inc. Class A (ZTS $113.83)
- $113.83 P/E (TTM): 19.58X Cap: $49.06B
- View ZTS Profile
- View Questions on ZTS
Pfizer CDR (CAD Hedged) (PFE $11.85)
- $11.85 P/E (TTM): 19.7X Cap: $208.22B
- View PFE Profile
- View Questions on PFE
Merck CDR (CAD Hedged) (MRK $24.86)
- $24.86 P/E (TTM): 15.14X Cap: $379.93B
- View MRK Profile
- View Questions on MRK

Q: As portfolios should be diversified, the following names are owned, yet are not doing well, except SYK/MRK. Are any of these outright sells or just not the flavour of the day?Thank you for your excellent advice!

Read Answer Asked by Neil on April 29, 2026

Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!

First Name *

Last Name *

E-mail *

Password *

I have read and agree to the Terms of Use